The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. - sprookjes - yvandenbroek - TriplyDB

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

http://www.wikidata.org/entity/Q33716356

about

Effect of redox modulating NRF2 activators on chronic kidney disease Discontinued in 2013: diabetic drugs.A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS Role of nuclear factor erythroid 2-related factor 2 in the oxidative stress-dependent hypertension associated with the depletion of DJ-1 The effect of Nrf2 pathway activation on human pancreatic islet cells.Diabetic nephropathy: What does the future hold?An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure.Betulinic acid enhances TGF-β signaling by altering TGF-β receptors partitioning between lipid-raft/caveolae and non-caveolae membrane microdomains in mink lung epithelial cells.Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice.Therapies on the Horizon for Diabetic Kidney Disease.Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.CDDO and Its Role in Chronic Diseases.Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.Salutary effect of pre-treatment with an Nrf2 inducer on ischemia reperfusion injury in the rat liver.Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.Synthetic Triterpenoid RTA dh404 (CDDO-dhTFEA) Ameliorates Acute Pancreatitis.Pharmacological activation of Nrf2 pathway improves pancreatic islet isolation and transplantation.Bardoxolone-the Phoenix?Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.Epigallocatechin-3-Gallate Attenuates Oxidative Stress and Inflammation in Obstructive Nephropathy via NF-κB and Nrf2/HO-1 Signalling Pathway Regulation.

P2860

Q26827726-B761D0D7-2059-47AB-85D0-7EAD7335712A Q34664870-D574B233-69FE-4590-B879-97D81EC6A3BB Q35533024-C33BFEE3-1728-4FB7-8C8C-DA2465A951D1 Q35611392-2C82A2CD-4091-4F57-9C5C-8589DAB01AF3 Q35674148-66B5EC30-6B96-4DDC-8955-B0E4C0278FE6 Q36441616-47CF372F-3B16-47DF-BF13-87E5E122A218 Q36606173-98403726-8734-4647-AC57-66FCBEC7A348 Q36625618-E915C5CE-4B56-4406-B837-D6C6108232ED Q36756653-5B52765B-A2F3-442D-95F5-77AD4749876F Q38605099-FDDE64DC-9018-4A51-B1FA-86FC367DB832 Q38786854-888D8B1E-7BCA-4EA4-BDF0-562587F805BB Q38807055-78A41CF0-E769-4D62-BB0B-EC1F91DA435F Q42172913-296F5A51-FF32-431C-A58C-1D7177BA0055 Q43086271-66289FEF-65F2-421C-A22E-DA80245F1E94 Q44545402-0E380D8F-74EE-440C-963C-CAAA94E9BADB Q46051686-12BCFE13-C3CA-4DC7-BABC-F249E002E455 Q46297577-578986E9-E6DC-4658-BF5E-46C9B0F8F914 Q49680688-6960DF19-4591-4BB5-A61C-38CA6EEBC78C Q50198506-46CDD106-50F9-4883-9698-A1A5A194C19F Q50282637-CBDAA08A-DD84-429C-B418-F16C4A6CAD5B

P2860

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

http://www.wikidata.org/entity/Q33716356

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@ast

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@en

type

label

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@ast

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@en

prefLabel

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@ast

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@en

P1433

Q33716356-E312968B-7193-4002-8DF6-C57888A16CF5

P1476

Q33716356-1B6505C3-8C79-4927-B387-CE26628B66B7

P2093

Q33716356-1949A83C-15A2-414C-B8B7-55326999719E

Q33716356-2102E529-125F-485B-8A5B-2BDB67B00C80

Q33716356-88B49BB6-534B-4F99-BEAA-2EFA383B3CC5

Q33716356-A110682C-438C-44BB-960C-EB72E716AD36

Q33716356-A5FFC36D-1F7A-49DD-9049-F41742F4A112

Q33716356-CED274F0-F06A-45F3-B379-279A75EFA76B

P2860

Q33716356-065F7DD2-E504-4475-A304-73F1655C03E8

Q33716356-0E06BCFD-10FA-426E-B44B-87D25E42CA37

Q33716356-1E76A080-F6C6-4BB8-B80A-E27B4D977912

Q33716356-20C1B2CE-22D4-4D70-893E-411809247363

Q33716356-21E57FAC-02B7-4CEC-BF17-642624C7E2A5

Q33716356-232F841C-748B-44CE-BE6A-84A9A6321C5E

Q33716356-2EA00C91-6526-4A68-8EFE-4932BFCF3EAF

Q33716356-30CEFCCE-0377-488E-A10E-D2AE5B0AEA89

Q33716356-38A425A0-EB4B-4752-AC88-49E7A21315B8

Q33716356-55D1C8F8-5CF4-49D6-9C67-9DE2EC399396

P304

Q33716356-EB2820F2-2931-4511-99BE-407EEDB0C02A

P31

Q33716356-25EB5A10-756A-49E8-B201-E806569F3829

P356

Q33716356-7A8336AA-E94A-4031-9084-F41098872DEC

P407

Q33716356-A4CDEB2A-9346-4B0E-90E9-DE04BD7D08A1

P433

Q33716356-15EDC20B-0640-43E3-9B72-E9A986ECBC80

P478

Q33716356-98A77D16-2849-4FFF-9E1A-7E819B98DAAF

P577

Q33716356-5FF553EC-C2A4-44CF-8057-B153497D738B

P5875

Q33716356-E39A72E7-55E1-419E-A853-D0F1FA3E583E

P698

Q33716356-0660960F-3976-4DEE-89CE-64508F7D11AA

P932

Q33716356-61114179-60BC-41A1-A5C1-78932A7C6BB0

P356

00498254.2013.852705

P1433

P1476

The synthetic triterpenoid RTA ...... s with chronic kidney disease.

@en

P2093

Colin J Meyer

http://www.w3.org/2001/XMLSchema#string

Jun Yuan

http://www.w3.org/2001/XMLSchema#string

Mahyar Khazaeli

http://www.w3.org/2001/XMLSchema#string

Mohammad A Aminzadeh

http://www.w3.org/2001/XMLSchema#string

Nosratola D Vaziri

http://www.w3.org/2001/XMLSchema#string

Scott A Reisman

http://www.w3.org/2001/XMLSchema#string

P2860

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

When NRF2 talks, who's listening?

Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.

Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

P304

570-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2013.852705

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258334759

http://www.w3.org/2001/XMLSchema#string

P698

24195589

http://www.w3.org/2001/XMLSchema#string

P932

4046874

http://www.w3.org/2001/XMLSchema#string